Silence Therapeutics PLC Silence Therapeutics Announces Board Change (2790Y)

TIDMSLN

RNS Number : 2790Y

Silence Therapeutics PLC

20 August 2018

Silence Therapeutics Announces Board Change

20 AUGUST 2018

Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases, announces today that Dr. Annalisa Jenkins is leaving her role as executive Chair and Director of the Company with immediate effect. Dr. Andy Richards, CBE, a non-executive Director of Silence Therapeutics since September 2016, is today assuming the role of non-executive Chair in an interim capacity to ensure a smooth transition. The Company has commenced a process to appoint a new Chair and will report further in due course.

Dr. David Horn Solomon, Chief Executive Officer of Silence, commented: "On behalf of the Company and my colleagues on the Board, we thank Annalisa Jenkins for her energetic and dedicated service to Silence Therapeutics during the past year. In a short period of time, Annalisa has been responsible for upgrading our R&D operations, and reshaping the company strategy. We wish her well with her portfolio of Board and non-Board roles and her future endeavours. Silence is now in a much better position to compete in the newly approved drug modality of RNAi, and we are excited to continue our drug development based upon our proprietary platform."

Enquiries:

 
 Silence Therapeutics plc                       Tel: [phone] 
  David Horn Solomon, Chief Executive Officer                   6900 
  Dr. Andy Richards CBE, Interim Chair 
  David Ellam, Chief Financial Officer 
 Peel Hunt LLP (Nominated Adviser and Broker)   Tel: [phone] 
  James Steel/ Oliver Jackson                                   8900 
 European IR                                    Tel: [phone] 
  Consilium Strategic Communications                            5700 
  Mary-Jane Elliott, Angela Gray 
  [e-mail] 
 US IR                                             Tel: [phone] 
  Burns McClellan                                               0006 
  John Grimaldi 
  [e-mail] 
 

Notes to Editors

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. For more information, please visit: http://www.silence-therapeutics.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

BOASELSASFASEEA

(END) Dow Jones Newswires

August 20, 2018 04:30 ET (08:30 GMT)